Furthermore, as glucagon receptor antagonism may result in dyslipidemia, hyperaminoacidemia and hepatic lipid deposition, it has been suggested that glucagon agonism may be of therapeutic relevance for treatment of type 2 diabetes [243]. The gene discussed is GCG; the disease is metabolic syndrome.